Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells

The standard treatment for Triple Negative Breast Cancer (TNBC) patients is cytotoxic chemotherapy, but it is restricted since the duration of response is usually short. Blocking the PD-1/PD-L1 pathway through monoclonal antibodies (mAbs) appears to be a promising therapeutic strategy for TNBC patie...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Immunol
Hlavní autoři: Juliá, Estefanía Paula, Amante, Analía, Pampena, María Betina, Mordoh, José, Levy, Estrella Mariel
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2018
Témata:
Immunology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6159755/
https://ncbi.nlm.nih.gov/pubmed/30294328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.02140
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky